Deerfield Hedge Fund Said to Get Subpoena Over Ties to D.C. Firm
(Bloomberg) -- Deerfield Management, a $7 billion firm that invests in health-care companies, has received a subpoena from U.S. authorities over its relationship with the founder of a Washington political-intelligence company, according to a person with direct knowledge of the matter.
Deerfield told investors in an Oct. 27 letter that the government's request relates to its dealings with David Blaszczak, the founder of Precipio Health Strategies, said the person who asked not to be named because the New York-based firm is private. Deerfield buys shares of health-care companies and also makes private equity investments, according to its website.
Deerfield officials declined to comment on the U.S. subpoena.
In its letter to investors, Deerfield said it's one of many companies that have received services from Blaszczak and that the government's interest in him has been documented in media reports, the person said. Blaszczak, a former federal employee at the Center for Medicare and Medicaid Services, is the focus of a U.S. investigation, the Wall Street Journal reported in August, citing people familiar with the probe.
Calls to Blaszczak from Bloomberg News weren't immediately returned.
Government Investigations
The Justice Department and Securities and Exchange Commission have been cracking down on hedge funds' use of firms that are paid to offer insights on industry trends and Washington policy that could move stock prices.
As part of a six-year nationwide probe, prosecutors have pursued cases in which so-called expert networks provided inside information on financial results of public companies. In June, the Justice Department and SEC accused a consultant named Gordon Johnston of providing illegal tips to hedge fund Visium Asset Management that he had received from a former colleague at the Food and Drug Administration. Johnston is cooperating with the government.
Blaszczak played a role in the government's investigation into Visium, according to the Wall Street Journal's August article. He is allegedly a “co-conspirator” and “political consultant” who helped the hedge fund make $285,000 in profits with non-public information tied to health-care spending cuts, the Journal reported. The newspaper said Blaszczak and his lawyer didn't respond to requests for comment.
To contact the reporter on this story: Matt Robinson in New York at mrobinson55@bloomberg.net. To contact the editors responsible for this story: Jesse Westbrook at jwestbrook1@bloomberg.net, Gregory Mott
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets
-
India Is Going Abroad For Critical Minerals. But It May Take Years To Pay Off | The Reason Why
Although India's steps are in the right direction, they remain modest compared with India's growing dependence.
-
When Everyone Has AI, What Gives You An Edge?
India's young workforce is entering an uncertain world of work where powerful AI tools are becoming widely accessible. The advantage will belong to those who combine deep expertise with digital fluency, and the distinctly human capabilities that technology cannot manufacture.
-
Wrong Labels, High Pesticide Residues Holding Back Agri Exports | The Reason Why
India needs stronger domestic food-safety and labelling standards, with best practices becoming part of everyday business for farmers, traders and food companies.